Korro Bio (NASDAQ:KRRO) Given Outperform Rating at William Blair

William Blair reiterated their outperform rating on shares of Korro Bio (NASDAQ:KRRO) in a report published on Wednesday,RTT News reports.

A number of other research firms have also weighed in on KRRO. HC Wainwright boosted their target price on Korro Bio from $100.00 to $115.00 and gave the stock a “buy” rating in a report on Friday, October 18th. Raymond James started coverage on shares of Korro Bio in a report on Monday, October 21st. They issued a “strong-buy” rating and a $153.00 price objective on the stock. Finally, Royal Bank of Canada raised their target price on shares of Korro Bio from $95.00 to $105.00 and gave the stock an “outperform” rating in a research note on Monday, October 21st. Five investment analysts have rated the stock with a buy rating and one has assigned a strong buy rating to the company’s stock. According to data from MarketBeat, the stock presently has an average rating of “Buy” and an average price target of $142.17.

Korro Bio Trading Down 15.6 %

Shares of NASDAQ KRRO traded down $10.13 during midday trading on Wednesday, reaching $55.01. 321,585 shares of the stock were exchanged, compared to its average volume of 69,636. Korro Bio has a 12 month low of $30.00 and a 12 month high of $98.00. The business has a 50-day simple moving average of $49.77 and a two-hundred day simple moving average of $46.92.

Korro Bio (NASDAQ:KRRO) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($2.26) earnings per share (EPS) for the quarter, beating the consensus estimate of ($2.55) by $0.29. Equities research analysts predict that Korro Bio will post -10.02 EPS for the current year.

Insider Activity

In other news, CFO Vineet Agarwal sold 10,216 shares of Korro Bio stock in a transaction dated Thursday, October 17th. The stock was sold at an average price of $78.26, for a total transaction of $799,504.16. The sale was disclosed in a document filed with the SEC, which is available through this hyperlink. 5.40% of the stock is owned by corporate insiders.

Institutional Trading of Korro Bio

A number of institutional investors and hedge funds have recently bought and sold shares of the stock. Bank of New York Mellon Corp acquired a new position in shares of Korro Bio in the second quarter worth approximately $649,000. Rhumbline Advisers bought a new position in Korro Bio in the 2nd quarter valued at about $279,000. Atlas Venture Life Science Advisors LLC boosted its stake in Korro Bio by 1.6% during the 2nd quarter. Atlas Venture Life Science Advisors LLC now owns 1,137,149 shares of the company’s stock valued at $38,515,000 after purchasing an additional 17,857 shares during the last quarter. Brown Brothers Harriman & Co. bought a new stake in Korro Bio during the 2nd quarter worth approximately $28,000. Finally, Tri Locum Partners LP purchased a new stake in shares of Korro Bio in the second quarter worth approximately $2,419,000. 13.18% of the stock is currently owned by institutional investors and hedge funds.

Korro Bio Company Profile

Korro Bio, Inc, a biopharmaceutical company, engages in the discovery, development, and commercialization of genetic medicines based on editing RNA for the treatment of rare and highly prevalent diseases primarily in the United States. Its lead product candidate is KRRO-110 which is in preclinical trials for the treatment of Alpha-1 Antitrypsin Deficiency (AATD).